Vaccines

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.

As the Federal Drug Administration (FDA) considers adding a third COVID-19 vaccine to the rollout, a multicenter study led by Vanderbilt University Medical Center will evaluate how effective the vaccines are in preventing hospitalization from COVID-19.

In the 351 days since the COVID-19 Command Center opened to steer Vanderbilt University Medical Center through the pandemic, the workforce stepped up and contributed, keeping the health system on track to deliver care even as the landscape quaked with new challenges.

As of Feb. 1,065 outpatients have received antibody infusions since the clinic opened on Nov. 18. Clinic officials estimated that the infusions have prevented about 70 patients from developing severe COVID-19 illness requiring hospitalization or emergency department evaluation.

In early 2020, several groups at Vanderbilt University Medical Center were busy planning an in-person event to announce the creation of Vanderbilt Health Employer Solutions, a team designed to provide workforce health and wellness services to businesses of all types and sizes. By March, it was clear that area employers needed a trusted source of information and support to manage the COVID-19 pandemic.

Health care workers, who have been disproportionately affected by the COVID-19 pandemic, will be the first tier of Vanderbilt University Medical Center employees to receive vaccine to prevent SARS-CoV-2 infection.

The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.